TW376386B - Bioregulatory active substance, method for its production and use thereof - Google Patents

Bioregulatory active substance, method for its production and use thereof

Info

Publication number
TW376386B
TW376386B TW085115731A TW85115731A TW376386B TW 376386 B TW376386 B TW 376386B TW 085115731 A TW085115731 A TW 085115731A TW 85115731 A TW85115731 A TW 85115731A TW 376386 B TW376386 B TW 376386B
Authority
TW
Taiwan
Prior art keywords
active substances
production
active substance
well
bioregulatory
Prior art date
Application number
TW085115731A
Other languages
English (en)
Chinese (zh)
Inventor
Franz Kerek
Original Assignee
Donatur Dr Kerek Cmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Donatur Dr Kerek Cmbh filed Critical Donatur Dr Kerek Cmbh
Application granted granted Critical
Publication of TW376386B publication Critical patent/TW376386B/zh

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/22—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
    • C12P17/181—Heterocyclic compounds containing oxygen atoms as the only ring heteroatoms in the condensed system, e.g. Salinomycin, Septamycin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
TW085115731A 1996-01-05 1996-12-18 Bioregulatory active substance, method for its production and use thereof TW376386B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19600301A DE19600301C2 (de) 1996-01-05 1996-01-05 Durch Cyclooligomerisierung des einfachen Kohlensuboxids C¶3¶O¶2¶ aufgebaute makrocyclische Verbindungen, Verfahren zu deren Herstellung und Gewinnung sowie deren Verwendung

Publications (1)

Publication Number Publication Date
TW376386B true TW376386B (en) 1999-12-11

Family

ID=7782233

Family Applications (1)

Application Number Title Priority Date Filing Date
TW085115731A TW376386B (en) 1996-01-05 1996-12-18 Bioregulatory active substance, method for its production and use thereof

Country Status (26)

Country Link
US (1) US6187810B1 (Direct)
EP (1) EP0874851B1 (Direct)
JP (1) JP4195089B2 (Direct)
KR (1) KR19990077000A (Direct)
CN (1) CN1209132A (Direct)
AR (1) AR005350A1 (Direct)
AT (1) ATE233768T1 (Direct)
AU (1) AU1307497A (Direct)
BG (1) BG102599A (Direct)
BR (1) BR9612430A (Direct)
CA (1) CA2241870A1 (Direct)
CZ (1) CZ208898A3 (Direct)
DE (2) DE19600301C2 (Direct)
EE (1) EE9800211A (Direct)
ES (1) ES2194128T3 (Direct)
HR (1) HRP970002A2 (Direct)
HU (1) HUP9904191A2 (Direct)
IL (1) IL125165A0 (Direct)
JO (1) JO1945B1 (Direct)
PL (1) PL327657A1 (Direct)
SI (1) SI0874851T1 (Direct)
SK (1) SK88598A3 (Direct)
TR (1) TR199801288T2 (Direct)
TW (1) TW376386B (Direct)
WO (1) WO1997025333A2 (Direct)
ZA (1) ZA9714B (Direct)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPO280796A0 (en) * 1996-10-07 1996-10-31 Austin Research Institute, The Methods of activating or enhancing FC receptors
DE10260537A1 (de) 2002-12-21 2004-07-15 Kerek, Franz, Dr. Peptide mit hohem Cysteingehalt
US20060067055A1 (en) * 2004-09-30 2006-03-30 Heffner Kenneth H Thermally conductive composite and uses for microelectronic packaging
EP1794223A1 (en) * 2004-09-30 2007-06-13 Honeywell International Inc. Thermally conductive composite and uses for microelectronic packaging
CN119081077B (zh) * 2024-09-26 2025-12-26 清华大学 一种聚吡喃酮、制备方法及应用
CN119613750B (zh) * 2024-12-10 2025-08-12 杭州师范大学 一种机械及pH双重调控的蝶形钾离子通道分子及其制备方法和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2565115A (en) 1948-10-28 1951-08-21 Squibb & Sons Inc Method of obtaining a conjugated estrogen preparation
US2720483A (en) 1951-02-21 1955-10-11 Olin Mathieson Method of obtaining a conjugatedestrogen preparation

Also Published As

Publication number Publication date
ATE233768T1 (de) 2003-03-15
HUP9904191A2 (hu) 2000-05-28
HRP970002A2 (en) 1998-04-30
CA2241870A1 (en) 1997-07-17
BG102599A (en) 1999-03-31
AR005350A1 (es) 1999-04-28
DE69626548T2 (de) 2003-12-24
JP4195089B2 (ja) 2008-12-10
DE19600301A1 (de) 1997-07-10
JO1945B1 (en) 1997-12-15
JP2000503015A (ja) 2000-03-14
EP0874851B1 (en) 2003-03-05
TR199801288T2 (xx) 1998-11-23
BR9612430A (pt) 1999-12-28
WO1997025333A3 (en) 1997-12-24
US6187810B1 (en) 2001-02-13
CN1209132A (zh) 1999-02-24
AU1307497A (en) 1997-08-01
SK88598A3 (en) 1998-12-02
EE9800211A (et) 1998-12-15
IL125165A0 (en) 1999-01-26
EP0874851A2 (en) 1998-11-04
CZ208898A3 (cs) 1998-10-14
ES2194128T3 (es) 2003-11-16
SI0874851T1 (en) 2003-10-31
DE19600301C2 (de) 1999-12-09
DE69626548D1 (de) 2003-04-10
ZA9714B (en) 1997-07-23
PL327657A1 (en) 1998-12-21
KR19990077000A (ko) 1999-10-25
WO1997025333A2 (en) 1997-07-17

Similar Documents

Publication Publication Date Title
DE69630214D1 (de) Benzamidin-derivate, deren herstellung und deren verwendung als anti-koagulantien
TWI224595B (en) New benzazepine derivatives, drugs containing these and use of the same for producing drugs
AU4384397A (en) Benzamidine derivatives substituted by cyclic amino acid and cyclic hydroxy acid derivatives and their use as anti-coagulants
AP9701019A0 (en) Phenylamino-substituted tricycle derivatives.
PL314187A1 (en) Novel derivatives of pyrazine carboxamide, method of obtaining them and their application in pharmaceutical composition
IE840302L (en) 3-(5-aminopentyl)amino-1-benzazepin-2-one-1-alkanoic acids.
AU5377698A (en) Substituted pyrrolyl compounds for the treatment of inflammation
BR9407910A (pt) Composto composiçao farmacêutica uso do composto processo de tratamento de distúrbios no sistema nervoso central e processo de preparaçao do composto
ATE223912T1 (de) Pyridylalkan-säureamide als cytostatika und immunosupressive arzneimittel
ZA971183B (en) Benzamidine derivatives substituted by amino acid and hydroxy acid derivatives and their use as anti-coagulants.
EP0119161A3 (en) Benzazoquinone and benzazoninone derivatives, process for their preparation, their pharmaceutical preparations as well as their therapeutic use
DE59208974D1 (de) Neue pyrazinderivative, ihre herstellung und verwendung
GR900100326A (en) Saccharin derivatives useful as proteolytic enzyme inhibitors and preparation thereof
NO307710B1 (no) Fremgangsmåte ved fremstilling av <beta>-laktamer
AU1428801A (en) Novel (1,2,3)-triazolo(4,5-D)pyrimidine compounds
PL305457A1 (en) Galantamine derivatives, method of obtaining them and their application as drugs
WO1994019343A3 (en) Novel use as anti-inflammatory agents for bis-heterocyclic compounds and pharmaceutical compositions thereof
MY117381A (en) Use of 1-hydroxy-2-pyridone for the treatment of seborrheic dermatitis
PL352476A1 (en) Novel derivatives of piperazinylalkylthiopyrimidine, parmacological compositions containing tese compounds and method of obtaining active substance
DE69120287D1 (en) Aminosulfonylharnstoff-acat-inhibitoren
JO1945B1 (en) A bioactive active substance and a way to prepare and use it
WO1998013009A3 (de) Verwendung von 1-hydroxy-2-pyridonen zur behandlung der seborrhoischen dermatitis
IL108193A0 (en) Benzoylecgonine, ecgonine and ecgonidine derivatives, pharmaceutical compositions containing the same, and methods for the preparation therof
BG101535A (en) 1,4-diaryl-2-fluoro-2-butene insecticide and acaricidal formulations
ATE229953T1 (de) Naphtho-imidazo(1,2-a)pyridin derivate, deren herstellung und deren verwendung in der behandlung von störungen des zentralnervensystems